Piper Sandler lowered the firm’s price target on Health Catalyst to $14 from $15 and keeps an Overweight rating on the shares following Q1 results and guidance. Specifically, Health Catalyst reiterated the FY24 outlook, guiding revenues to $304M-$312M, adjusted EBITDA to $24M-$26M, net new DOS adds to the mid-teens, and dollar-based retention to 104%-110%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst to Participate in Upcoming Investor Conferences
- Health Catalyst price target lowered to $13 from $14 at Wells Fargo
- Health Catalyst sees FY24 revenue $304M-$312M, consensus $308.68M
- Health Catalyst sees Q2 revenue $73.5M-$76.5M, consensus $75.55M
- Health Catalyst reports Q1 adjusted EPS 5c, consensus 3c